S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update
Open Access
- 15 May 2020
- journal article
- research article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 18 (5), 516-526
- https://doi.org/10.1111/ddg.14097
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroidsJournal of the American Academy of Dermatology, 2013
- Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsoneIndian Journal of Dermatology, 2012
- Efficacy of Dapsone in the Treatment of Pemphigus and PemphigoidAmerican Journal of Clinical Dermatology, 2009
- Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Randomized controlled open-label trial of four treatment regimens for pemphigus vulgarisJournal of the American Academy of Dermatology, 2007
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusThe New England Journal of Medicine, 2007
- Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorptionClinical and Experimental Dermatology, 2006
- Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximabBritish Journal of Dermatology, 2003
- Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigusBritish Journal of Dermatology, 2003